Multigene expression tests have become part of standard diagnostic tests in ER-positive Her2-negative early breast cancer, in nodal-negative and nodal-positive patients providing risk scores to tailor the decision between adjuvant endocrine therapy alone or in combination with chemotherapy [10–12, 49, 65, 66]. The gene discussed is ERBB2; the disease is breast carcinoma.